Iromate 100 mg/5 ml (IV Injection or Infusion)
5 ml ampoule: ৳ 326.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Iron sucrose |
| Company | Novatek pharmaceuticals ltd |
Indications
- Rapid Iromate supply
- Inability to tolerate oral Iromate therapy
- Non-compliance with oral Iromate therapy
- Active inflammatory bowel disease
- Non-dialysis dependent-chronic kidney disease (NDD-CKD)
- Hemodialysis dependent-chronic kidney disease (HDD-CKD)
- Peritoneal dialysis dependent-chronic kidney disease (PDD-CKD)
- Iromate deficiency anemia in surgical patients
- Iromate deficiency anemia in blood donors
- Iromate deficiency anemia in postpartum patients
Pharmacology
- Therapeutic class: haematinic
- Contains approximately 30% Sucrose w/v
- pH range of 10.5-11.1
- Dissociates into Iron and Sucrose
- Iron transfer from blood to liver and bone marrow
- Ferritin binds and sequesters Iron
- Iron binds to plasma transferrin for tissue supply
Dosage
- Adult dosage: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week
- Children dosage: Not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight
Administration
- Intravenous injection at recommended rate
- Maximum 10 ml Iron Sucrose Injection (200 mg Iron) per injection
- Test dose before therapeutic dose in new patients
- Preferably administered by drip infusion
Interaction
- Should not be administered concomitantly with oral iron preparations
- Oral Iromate therapy should not be given until 5 days after last injection
Contraindications
- Evidence of Iron overload
- Known hypersensitivity to Iron Sucrose or its inactive components
- Anaemia not caused by Iron deficiency
- History of allergic disorders, liver disease, or infections
Side Effects
- Hypotension
- Leg cramps
- Nausea
- Headache
- Vomiting
- Diarrhea
- Fever
- Pain
- Asthenia
- Malaise
- Accidental injury
- Hypertension
- Hypervolemia
- Abdominal pain
- Elevated liver enzymes
- Dizziness
- Musculoskeletal pain
- Dyspnea
- Pneumonia
- Cough
- Pruritus
- Application site reaction
- Hypersensitivity reactions
- Anaphylactoid reactions
Pregnancy & Lactation
- Pregnancy Category-B
- Use during pregnancy only if clearly needed
- Caution advised when administered to nursing women
Precautions & Warnings
- Periodic monitoring of hematologic and haematinic parameters required
- Caution regarding tissue Iron overload
- Monitoring of serum Iromate values 48 hours after IV dosing
- Caution in patients with hypersensitivity reactions
- Monitoring for hypotension
- Pediatric use not established
- No significant safety differences observed in geriatric use
- Caution in administration to dialyser, HDD-CKD, and NDD-CKD patients
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No significant safety differences observed in geriatric use
Overdose Effects
- Accumulation of Iron leading to hemosiderosis
- Monitoring of serum ferritin and transferrin saturation advisable
- Symptoms include hypotension, headache, vomiting, nausea, dizziness, joint aches, and more
- Management with IV fluids, hydrocortisone, and antihistamines
- Caution in infusing Iromate at a slower rate
Therapeutic Class
- Parenteral Iron Preparations
Storage Conditions
- Store in a cool (15°C- 30°C) & dry place
- Protected from light
- Keep out of the reach of children
- Do not freeze